Researchers from China Pharmaceutical University and collaborators have identified various naphthalene and indane derivatives as selective USP7 inhibitors.
CSPC Megalith Biopharmaceutical Co. Ltd. has described antibody-drug conjugates (ADCs) comprising anti-tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) antibodies covalently linked to cytotoxic drugs reported to be useful for the treatment of pancreatic and breast cancer.
Cptx GmbH’s QUIET-CAR collaborative project with Nanocell Therapeutics Inc. has been awarded a Eurostars Grant from the EU through the Horizon Europe program and Eureka Network. The QUIET-CAR project aims to develop targeted lipid nanoparticles carrying novel immune-silent single-stranded DNA (ssDNA) for in vivo CAR T therapy.
Researchers from the University of Tennessee and collaborating institutions have investigated in preclinical models the use of an oncolytic herpes simplex virus (oHSV) armed with the immune-stimulating cytokine interleukin-12 (IL-12) as a potential treatment for glioblastoma. They published their results in Molecular Therapy: Oncology.
Pilatus Biosciences Inc. has announced a clinical trial collaboration with F. Hoffmann-La Roche Ltd. in support of Pilatus’ upcoming first-in-human phase I trial evaluating PLT-012 in combination with atezolizumab in patients with hepatocellular carcinoma (HCC).
Evolveimmune Therapeutics Inc. has gained IND clearance from the U.S. FDA for EVOLVE-104, a novel trispecific T-cell engager for the treatment of solid tumors. The company will begin a phase I trial this year.
Lung cancer, which often occurs as lung adenocarcinoma, is the leading cause of cancer-related death worldwide. At least 70% of lung adenocarcinoma patients fail to show long-term benefit from immune checkpoint inhibitors, highlighting the need to identify in advance those more likely to benefit.
Endometrial cancer is the second most prevalent gynecological malignancy. Current standard treatments for endometrial cancer typically include a combination of surgery, radiation therapy and, in some cases, chemotherapy or hormonal therapy, depending on the tumor stage and molecular characteristics. However, the outcomes for metastatic and recurrent cases remain poor.
Prognosis is extremely poor for patients with head and neck squamous cell carcinoma (HNSCC), which accounts for around 90% of all head and neck cancer. Especially in the more aggressive subtype of HNSCC that is not associated with human papilloma virus infection, the natural killer cells that could fight HNSCC tumors are inhibited within the tumor microenvironment, in part because of the hypoxic conditions.
Radiopharm Theranostics Ltd. announced that the U.S. FDA has cleared the IND application for betabart (RV-01), its Lu177-B7H3 monoclonal antibody designed with strong affinity for the 4Ig isoform of B7-H3 that is highly expressed in tumors and not in healthy tissues.
RSS
